Publication date: November–December 2026 Source: Steroids, Volumes 235–236 Author(s): Jing Miao, Lobke F. Zijlstra, Marieke Heijink, Iulia Sidorov, Jamie I. van der Vaart, Christoph Müller, Franz Bracher, Menno P.J. de Winther, Martin Giera, Annette E. Neele, Patrick C.N. Rensen, Sander Kooijman
DHCR24 inhibition upregulates desmosterol without promoting regression of atherosclerotic plaques in APOE*3-Leiden.CETP mice. // Steroids. – URL: https://www.sciencedirect.com/science/article/pii/S0039128X26000929?dgcid=rss_sd_all
DHCR24 inhibition upregulates desmosterol without promoting regression of atherosclerotic plaques in APOE*3-Leiden.CETP mice. Steroids. https://www.sciencedirect.com/science/article/pii/S0039128X26000929?dgcid=rss_sd_all
“DHCR24 inhibition upregulates desmosterol without promoting regression of atherosclerotic plaques in APOE*3-Leiden.CETP mice.” Steroids.
@article{article95239,
title = {DHCR24 inhibition upregulates desmosterol without promoting regression of atherosclerotic plaques in APOE*3-Leiden.CETP mice},
journal = {Steroids},
url = {https://www.sciencedirect.com/science/article/pii/S0039128X26000929?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...